• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Minerva Neurosciences Inc

    4/23/26 7:02:08 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NERV alert in real time by email
    DEFA14A 1 d109656ddefa14a.htm DEFA14A DEFA14A

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.  )

     

     

    Filed by the Registrant ☒    Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under § 240.14a-12

    MINERVA NEUROSCIENCES, INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item  25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


    LOGO

    Your Vote Counts!MINERVA NEUROSCIENCES, INC.1500 DISTRICT AVEBURLINGTON, MA 01803MINERVA NEUROSCIENCES, INC.2026 Annual MeetingVote by June 2, 202611:59 PM ETYou invested in MINERVA NEUROSCIENCES, INC. and it’s time to vote!You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding theavailability of proxy materials for the stockholder meeting to be held on June 3, 2026.Get informed before you voteView the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) byrequesting prior to May 20, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings,you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending anemail, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive apaper or email copy.For complete information and to vote, visit www.ProxyVote.comControl #Vote Virtually at the Meeting*June 3, 20268:30 AM EDTSmartphone usersPoint your camera here andvote without entering acontrol number*Please check the meeting materials for any special requirements for meeting attendance.


    LOGO

    THIS IS NOT A VOTABLE BALLOTThis is an overview of the proposals being presented at theupcoming stockholder meeting. Please follow the instructions onthe reverse side to vote these important matters.Vote at www.ProxyVote.comPrefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.Voting ItemsBoardRecommendsV94044-P483771. To elect two Class III directors each to hold office until 2029 Annual Meeting of Stockholders.Nominees: For01) David Kupfer02) Jan van Heek2. To approve an amendment of the Company’s Amended and Restated Certificate of Incorporation, as amended (the“Existing Charter”), to reflect Delaware Law provisions allowing for the exculpation of certain officers. For3. To approve an amendment of the Existing Charter to eliminate the exclusive forum provision. For4. To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in theaccompanying proxy statement. For5. To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of theCompany’s named executive officers. 1 Year6. To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independentregistered public accounting firm of the Company for its fiscal year ending December 31, 2026. ForNOTE: The proxies are authorized to vote in their discretion on such other business as may properly come before themeeting or any adjournment or postponement thereof.Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.V94044-P48377

    Get the next $NERV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NERV

    DatePrice TargetRatingAnalyst
    4/15/2026$14.00Mkt Outperform
    Citizens
    3/4/2022$10.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NERV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Minerva Announces Leadership Transition

    BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced a leadership transition with the appointment of Jim O'Connor as Chief Business Officer (CBO), effective April 21, 2026, as Geoff Race, the Company's President, has elected to leave the company. Mr. Race will continue to be involved with Minerva as a consultant. Mr. Race joined Minerva in 2010 and went on to serve in multiple executive roles including Executive Vice President and Chief Financial Officer, Chief Business Officer, and most recently President

    4/2/26 4:05:00 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

    Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population Efficacy topline data expected 2H 2027 BURLINGTON, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that the first patient has been screened in its global, confirmatory Phase 3 clinical trial evaluating roluperidone as monotherapy for the treatment of negative symptoms of schizophrenia. Negative symptoms, including avolition (severe lack of motivat

    3/31/26 4:05:00 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

    Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the second half of 2027 BURLINGTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the presentation of clinical data from its open‑label safety trial evaluating roluperidone co‑administered with olanzapine at the 2026 Schizophrenia International Research Society (SIRS) Annual Congress, held March 25

    3/25/26 4:05:00 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NERV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by O'Connor James Joseph

    4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

    4/22/26 4:55:18 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider O'Connor James Joseph

    3 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

    4/22/26 4:53:56 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kaul Inderjit

    4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

    4/1/26 4:15:08 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NERV
    SEC Filings

    View All

    SEC Form DEFA14A filed by Minerva Neurosciences Inc

    DEFA14A - Minerva Neurosciences, Inc. (0001598646) (Filer)

    4/23/26 7:02:08 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Minerva Neurosciences Inc

    DEF 14A - Minerva Neurosciences, Inc. (0001598646) (Filer)

    4/23/26 7:00:34 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Minerva Neurosciences Inc

    PRE 14A - Minerva Neurosciences, Inc. (0001598646) (Filer)

    4/10/26 9:20:28 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NERV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citizens initiated coverage on Minerva Neurosciences with a new price target

    Citizens initiated coverage of Minerva Neurosciences with a rating of Mkt Outperform and set a new price target of $14.00

    4/15/26 8:09:21 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Minerva Neurosciences with a new price target

    HC Wainwright & Co. reiterated coverage of Minerva Neurosciences with a rating of Buy and set a new price target of $5.00 from $10.00 previously

    3/4/22 6:14:09 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NERV
    Leadership Updates

    Live Leadership Updates

    View All

    Minerva Announces Leadership Transition

    BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced a leadership transition with the appointment of Jim O'Connor as Chief Business Officer (CBO), effective April 21, 2026, as Geoff Race, the Company's President, has elected to leave the company. Mr. Race will continue to be involved with Minerva as a consultant. Mr. Race joined Minerva in 2010 and went on to serve in multiple executive roles including Executive Vice President and Chief Financial Officer, Chief Business Officer, and most recently President

    4/2/26 4:05:00 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

    BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successfully raising up to $200 million in a private placement to fund a confirmatory Phase 3 trial for roluperidone for the treatment of negative symptoms in patients with schizophrenia, resubmission of it

    11/19/25 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Announces Promotion of Geoff Race to President

    Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA WALTHAM, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that Geoff Race, current Executive Vice President, Chief Financial Officer and Chief Business Officer of Minerva, has been promoted to President. Minerva's Senior Vice President and Chief Accounting Officer, Frederick Ahlholm, has been promoted to Chief Financial Officer. The appointments are effective immediately. These latest leadership

    10/11/21 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NERV
    Financials

    Live finance-specific insights

    View All

    Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

    BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter ended March 31, 2023. "The first quarter saw the achievement of a significant milestone for our investigational drug, roluperidone, and for Minerva, as the U.S. Food and Drug Administration (FDA) filed our New Drug Application (NDA) for roluperidone for the treatment of negative symptoms of schizophrenia on April 27, 2023. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of

    5/15/23 7:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

    BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release first quarter 2023 financial results and business updates on Monday, May 15, 2023. The Company will host a webcast that day at 8:30 a.m. Eastern Time to discuss the results and updates. The live conference call may be accessed here and on the Company's website under Events and Presentations. The archived webcast will be available on the Company's website beginning approximately two hours after the event for 90 days. About Miner

    5/8/23 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates

    BURLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2022. Corporate Update "In 2022, we had multiple interactions with the FDA regarding the regulatory path forward for our lead compound, roluperidone. After submitting an NDA for roluperidone to the FDA in August, we received a Refuse to File letter (RTF) in the fall, which was upheld following another meeting with the FDA. We remain committed to developing roluperid

    3/8/23 7:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NERV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Minerva Neurosciences Inc

    SC 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)

    11/12/24 10:32:12 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Minerva Neurosciences Inc

    SC 13G - Minerva Neurosciences, Inc. (0001598646) (Subject)

    2/9/24 9:28:31 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Minerva Neurosciences Inc (Amendment)

    SC 13G/A - Minerva Neurosciences, Inc. (0001598646) (Subject)

    1/18/24 10:21:16 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care